对于糖尿病患者来说,具有临床意义的金融毒性类别
Minal R Patel1, Jonathan P Troost2, Michele Heisler3,4
1Department of Health Behavior and Health Equity, University of Michigan, 1415 Washington Heights, SPH 1, Room 3810, Ann Arbor, MI, 48109, USA. minalrp@umich.edu.
Journal of patient-reported outcomes
|January 6, 2025
概括
糖尿病的财务毒性是使用COmprehensiveScore用于慢性疾病治疗的财务毒性-功能评估 (COST-FACIT) 来识别的. 26分可靠地识别出高财务毒性,有助于对受影响患者的临床支持.
科学领域:
- 内分泌学 在内分泌学.
- 卫生经济学 卫生经济学
- 心理社会医学 心理社会医学
背景情况:
- 对于患有糖尿病的成年人来说,金融毒性是一个很大的负担.
- 慢性疾病治疗的财务毒性-功能性评估 (COST-FACIT) 的综合评分用于评估财务毒性.
- 需要提高COST-FACIT的解释性和临床实用性.
研究的目的:
- 通过使用COST-FACIT,在患有糖尿病的成年人中确定不同的金融毒性类别.
- 提高COST-FACIT的临床实用性,用于识别经历金融毒性的糖尿病患者.
主要方法:
- 隐性类分析应用于600名患有1型或2型糖尿病和高A1c的成年人样本.
- 根据COST-FACIT得分模式确定了患者子组.
主要成果:
- 确定了三个不同的金融毒性类别:高,中,低.
- 高财务毒性的预测因素包括财务压力,适应不良,并发症,药物负担,糖尿病困扰,抑郁症状,较低的社会经济地位和人口因素等指标.
- 26的COST-FACIT得分显示了高财务毒性的强有力的预测价值 (PPV 76%,NPV 93%).
结论:
- COST-FACIT可靠地识别出患有糖尿病的个人经历了高度的财务毒性.
- 在临床实践中实施26的确定的COST-FACIT切割分数可以帮助识别需要额外支持的金融毒性患者.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
501
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
501
Pathophysiology of Diabetes
860
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
860
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
152
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
152


